Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, will attend the upcoming conference set to run ...

Samsung Biologics has signed a contract worth 111.2 billion won ($77 million) with an undisclosed U.S. pharmaceutical firm to provide contract manufacturing organization (CMO) services.

Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability ...

Korean biopharmaceutical firms Samsung Biologics, Celltrion, and Lotte Biologics will showcase their advancements at the J.P.

"We see great potential in Generate to develop first- and best-in-class therapeutics," said John Rim, President and CEO of Samsung Biologics. "Leveraging Generate's strengths in AI and machine ...

Threading quality into every step: One-stop manufacturing at Samsung Biologics Samsung Biologics, a fully integrated CDMO, is dedicated to ensuring high-quality production through its ...

Samsung Biologics announced on the 10th that it has received certification as a health-friendly corporation in the '2024 Health-Friendly Corporation Certification Project' organized by the ...

Samsung Biologics announced on the 17th that it has been included in the Dow Jones Sustainability Indices World for four consecutive years. The Dow Jones Sustainability Indices World is a global ...

Lotte Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) established in 2022, is ...

Samsung Biologics was recognized for its dedication to embed sustainable business practices across its operations, particularly robust environmental efforts, including progress toward achieving ...

The investment was made via the Samsung Life Science Fund, which was created jointly between Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation.

Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management ...